-
放射性核素68Ga标记的成纤维细胞激活蛋白抑制剂(fibroblast activation protein inhibitor, FAPI)是近年来被研发的新型广谱PET/CT显像剂,其在恶性肿瘤、心肌梗死、器官纤维化和慢性炎症等方面应用广泛 [1-2]。由于68Ga-FAPI在肝脏、肠道等器官中的非特异性摄取较低,且消化系统恶性肿瘤的靶/非靶比值较高,因此68Ga-FAPI PET/CT在消化系统肿瘤的诊治、分期、指导肿瘤放疗靶区勾画等方面显示出较好的应用潜力。笔者就近年来有关68Ga-FAPI PET/CT在食管、胃、结直肠、肝和胰腺等消化系统恶性肿瘤中的应用研究进展进行综述,以期为临床医师对消化系统恶性肿瘤的诊治和疗效评估等提供参考。
68Ga-FAPI PET/CT在消化系统恶性肿瘤中的应用研究进展
Research progress on the application of 68Ga-FAPI PET/CT in digestive system malignant tumors
-
摘要: 成纤维细胞激活蛋白(FAP)在恶性肿瘤间质中高表达。近年来,68Ga标记的FAP抑制剂(FAPI)广泛应用于临床研究,特别是在消化系统恶性肿瘤的诊断、远处转移的评估、辅助勾画肿瘤放疗靶区等方面具有一定优势。笔者就68Ga-FAPI PET/CT在常见消化系统恶性肿瘤中的应用研究进展进行综述,以期为临床医师对消化系统恶性肿瘤的诊断和治疗提供参考。
-
关键词:
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 镓放射性同位素 /
- 消化系统肿瘤 /
- 成纤维细胞激活蛋白抑制剂
Abstract: Fibroblast-activated protein (FAP) is overexpressed in the tumor stroma. In recent years, 68Ga-labelled FAP inhibitors (FAPI) have been widely used in clinical research, it has certain advantages in the diagnosis of digestive system malignant tumors, the evaluation of distant metastasis, and the assistance of delineate target volume. In this paper reviews the research progress of 68Ga-FAPI PET/CT in common digestive system malignant tumours, in order to provide a reference for clinicians in the diagnosis and treatment of digestive system malignant tumors. -
[1] Chen HJ, Pang YZ, Wu JX, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1820−1832. DOI: 10.1007/s00259-020-04769-z. [2] Windisch P, Zwahlen DR, Giesel FL, et al. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review[J/OL]. EJNMMI Res, 2021, 11(1): 18[2023-01-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-021-00761-2. DOI: 10.1186/s13550-021-00761-2. [3] Ping QR, Yan RP, Cheng X, et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions[J]. Cancer Gene Ther, 2021, 28(9): 984−999. DOI: 10.1038/s41417-021-00318-4. [4] Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts[J]. Nat Rev Cancer, 2020, 20(3): 174−186. DOI: 10.1038/s41568-019-0238-1. [5] Yazbeck R, Jaenisch SE, Abbott CA. Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein[J]. Protoplasma, 2018, 255(1): 375−386. DOI: 10.1007/s00709-017-1129-5. [6] Rettig WJ, Garin-Chesa P, Beresford HR, et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells[J]. Proc Natl Acad Sci USA, 1988, 85(9): 3110−3114. DOI: 10.1073/pnas.85.9.3110. [7] Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415−1422. DOI: 10.2967/jnumed.118.210443. [8] Dębiec K, Wydmański J, d'Amico A, et al. The application of 18F-FDG-PET/CT in gastric cancerstaging and factors affecting its sensitivity[J]. Hell J Nucl Med, 2021, 24(1): 66−74. DOI: 10.1967/s002449912308. [9] Qin CX, Song YMH, Gai YK, et al. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management[J]. Eur J Nucl Med Mol Imaging, 2022, 49(12): 4228−4240. DOI: 10.1007/s00259-022-05847-0. [10] Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(2): 743−750. DOI: 10.1007/s00259-021-05494-x. [11] Kömek H, Can C, Kaplan İ, et al. Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(11): 3898−3909. DOI: 10.1007/s00259-022-05839-0. [12] Koerber SA, Staudinger F, Kratochwil C, et al. The role of 68Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl Med, 2020, 61(9): 1331−1336. DOI: 10.2967/jnumed.119.237016. [13] 覃春霞, 宋杨美惠, 刘芳, 等. 68Ga-FAPI PET对结直肠癌再分期的诊断价值及对治疗决策的影响[J]. 中华核医学与分子影像杂志, 2021, 41(12): 717−721. DOI: 10.3760/cma.j.cn321828-20210901-00306.
Qin CX, Song YMH, Liu F, et al. Diagnostic value of 68Ga-FAPI PET for restaging and its impact on treatment decision in patients with colorectal cancer[J]. Chin J Nucl Med Mol Imaging, 2021, 41(12): 717−721. DOI: 10.3760/cma.j.cn321828-20210901-00306.[14] Marisa L, Blum Y, Taieb J, et al. Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer[J]. Clin Cancer Res, 2021, 27(17): 4768−4780. DOI: 10.1158/1078-0432.CCR-21-0529. [15] Strating E, Wassenaar E, Verhagen M, et al. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging[J]. Br J Cancer, 2022, 127(1): 145−155. DOI: 10.1038/s41416-022-01748-z. [16] Guo W, Pang YZ, Yao LL, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1604−1617. DOI: 10.1007/s00259-020-05095-0. [17] Shi XM, Xing HQ, Yang XB, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1593−1603. DOI: 10.1007/s00259-020-05070-9. [18] Wang H, Zhu WW, Ren SH, et al. 68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 693640. DOI: 10.3389/fonc.2021.693640. [19] Zhang ZY, Jia GR, Pan GX, et al. Comparison of the diagnostic efficacy of 68Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2877−2888. DOI: 10.1007/s00259-022-05729-5. [20] Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas[J]. J Nucl Med, 2021, 62(6): 779−786. DOI: 10.2967/jnumed.120.253062. [21] Pang YZ, Zhao L, Shang QH, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1322−1337. DOI: 10.1007/s00259-021-05576-w. [22] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801−805. DOI: 10.2967/jnumed.119.227967. [23] Polack M, Hagenaars SC, Couwenberg A, et al. Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT[J]. Clin Transl Oncol, 2022, 24(9): 1776−1784. DOI: 10.1007/s12094-022-02832-9. [24] Fu LL, Huang S, Wu HB, et al. RETRACTED ARTICLE: superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer[J]. Eur Radiol, 2022, 32(9): 6281−6290. DOI: 10.1007/s00330-022-08743-1. [25] Moradi F, Iagaru A. Will FAPI PET/CT replace FDG PET/CT in the next decade? Counterpoint–No, not so fast![J]. AJR Am J Roentgenol, 2021, 216(2): 307−308. DOI: 10.2214/AJR.20.23794. [26] Zhao L, Pang YZ, Luo ZM, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 1944−1955. DOI: 10.1007/s00259-020-05146-6. [27] Mo SB, Cai GX. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016: 1516259. DOI: 10.1155/2016/1516259. [28] Alan-Selçuk N, Ergen S, Demirci E, et al. [68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach[J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4523−4524. DOI: 10.1007/s00259-021-05213-6. [29] Fu LL, Hu KZ, Tang GH, et al. [68Ga]Ga-FAPI-04 PET/CT imaging in signet-ring cell carcinoma of sigmoid colon[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1690−1691. DOI: 10.1007/s00259-020-05155-5. [30] Şahin E, Elboğa U, Çelen YZ, et al. Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer[J]. Eur J Radiol, 2021, 142: 109867. DOI: 10.1016/j.ejrad.2021.109867. [31] Pang YZ, Zhao L, Luo ZM, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers[J]. Radiology, 2021, 298(2): 393−402. DOI: 10.1148/radiol.202020 3275. [32] Gong WD, Yang X, Wu JH, et al. 68Ga-FAPI PET/CT imaging of multiple muscle metastases of pancreatic cancer[J]. Clin Nucl Med, 2022, 47(1): 73−75. DOI: 10.1097/RLU.0000000000003888. [33] Liu QF, Shi S, Xu XP, et al. The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(4): 1248−1249. DOI: 10.1007/s00259-020-04997-3. [34] Rao ZJ, Wu J, Jiang GH, et al. Cardiac metastasis from esophageal carcinoma detected on 18F-FDG PET/CT and 68Ga-FAPI PET/CT scan[J]. J Nucl Cardiol, 2022, 29(6): 3590−3592. DOI: 10.1007/s12350-021-02645-3. [35] Ristau J, Giesel FL, Haefner MF, et al. Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer[J]. Mol Imaging Biol, 2020, 22(6): 1495−1500. DOI: 10.1007/s11307-020-01548-y. [36] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051−2058. DOI: 10.1016/S0140-6736(18)32487-5. [37] Liermann J, Syed M, Ben-Josef E, et al. Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer[J/OL]. Cancers (Basel), 2021, 13(4): 796[2023-01-08]. https://www.mdpi.com/2072-6694/13/4/796. DOI: 10.3390/cancers13040796. [38] Chen HJ, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings[J]. Eur J Nucl Med Mol Imaging, 2021, 48(1): 73−86. DOI: 10.1007/s00259-020-04940-6. [39] Yang X, Huang YL, Mou CR, et al. Chronic colitis mimicking malignancy on 68Ga-FAPI PET/CT[J]. Clin Nucl Med, 2022, 47(2): 159−160. DOI: 10.1097/RLU.0000000000003793.
计量
- 文章访问数: 6167
- HTML全文浏览量: 5441
- PDF下载量: 26